FENC
Fennec Pharmaceuticals Inc.
NASDAQHealthcareBiotechnologyUS
Rating:D+
Company Profile
CEO
Jeffrey S. Hackman
IPO Date
2017-09-15
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
Fennec Pharmaceuticals Inc.
CEO
Jeffrey S. Hackman
IPO Date
2017-09-15
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
| 168 |
| $0.00 |
| 1 Jun 2026 | Sayad Pierre Sargis | Chief Medical Officer | A-Award | Acquired | 168 | $0.00 |
| 1 Jun 2026 | Hackman Jeffrey S. | director, officer: Chief Executive Officer | A-Award | Acquired | 1,159 | $0.00 |
| 1 Jun 2026 | Andrade Robert | CHIEF FINANCIAL OFFICER | A-Award | Acquired | 1,703 | $0.00 |
| 12 May 2026 | RALLIS CHRIS A | director | M-Exempt | Acquired | 14,344 | $2.44 |
| 12 May 2026 | RALLIS CHRIS A | director | S-Sale | Disposed | 8,346 | $7.04 |
| 12 May 2026 | RALLIS CHRIS A | director | M-Exempt | Disposed | 14,344 | $2.44 |
| 1 May 2026 | Raykov Rosty | director | M-Exempt | Acquired | 2,778 | $0.00 |
| 1 May 2026 | Raykov Rosty | director | M-Exempt | Acquired | 15,598 | $2.45 |